Coronavirus

Tom Walker of Rev1 Ventures addresses the question of whether investors should back biotech start-ups that focus on the coronavirus and other potential pandemics. Here's what you should know.

The private markets advisory firm believes the pandemic has created even greater investment opportunities in the late-stage and growth equity sectors.

Appetite for biopharma is on the rise as investors want to back scientific advances and the recession-proof sector, and generalist VCs don’t want to miss out on potential outsized returns.

Mark Sherman of Telstra Ventures found that investing in Springboard in a virtual deal could be done. It just required a lot of phone calls.

As more venture firms become accustomed to virtual pitches, they’re emphasizing reference checks and setting up multiple Zoom calls as a way to verify their investments and better get to know the founders.

Boston-based Brio Systems, an employer COVID-19 testing platform, has raised $1.9 million in seed funding.

William Taranto of the Merck Global Health Innovation Fund writes how the switch to working from home can make investors more productive. But the downside is loss of personal interaction.

We all are aware of how covid-19 is impacting our lives. But I wonder how due diligence and the art of picking deals will be affected long-term.

Times are difficult right now, but promising signs in regard to deals terms, impact investing and engagement are boding well, writes Oliver Libby, managing partner and co-founder of venture firm Hatzimemos / Libby.

VC investment in biopharma and health tech continues to soar amid the covid-19 pandemic.